Skip to main content
. Author manuscript; available in PMC: 2010 Jan 22.
Published in final edited form as: J Med Chem. 2009 Jan 22;52(2):247–258. doi: 10.1021/jm800174p

Figure 6.

Figure 6

Schematic illustration of the effect of a MOP agonist/CCK2 antagonist bivalent ligand on the equilibrium between a mixture of MOP receptor (MOPR) and cholecystokinin receptors (CCK2R). Note that the bivalent ligand induces heterodimerization through constraint imposed by its spacer.